Apogee Therapeutics, Inc.
NASDAQ:APGEBiotechnology
+$1.05 today
- Market cap
- $8.36B
- Beta
- 0.62
- P/E (TTM)
- -22.7
- EPS (TTM)
- -$3.94
Volume 0.00M
Average 0.97M
APGE Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Apogee Therapeutics, Inc.NASDAQ: APGE
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin growth accelerates
Q2 FY2026 selling, general & admin of $24.34M rose 42.0% year over year, ahead of the +33.3% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 13.0% from the prior quarter. Over 3 fiscal years it compounded at +188.9% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 11 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +44.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $24.34M+13.0% QoQ
- Last fiscal yearDec 2025
- $70.88M+44.6% YoY
- LTMJun 2026
- $83.07M+33.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +42.0% | -100.0% | -142.0 pp |
| 1 year | +44.6% | -100.0% | -144.6 pp |
| 3-year CAGR | +188.9% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 70.88M USD
- Year-over-year change
- +44.6%
- 3-year CAGR
- +188.9%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.88M | +44.6% |
| FY2024 | 2024-12-31 | 49.01M | +99.4% |
| FY2023 | 2023-12-31 | 24.58M | +735.7% |
| FY2022 | 2022-12-31 | 2.94M | — |
Selling, General & Admin vs competitors
How APGE compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +33.3% is the 5th highest of 10, against a peer median of +24.7%.
- Over three fiscal years its annual growth of +188.9% compares with a peer median of +25.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
AAPGAscentage Pharma Group International | FY2025 | CN¥522.67M CNY | +36.4% | +16.8% | 93.6% |
| LTM Sep 2026 | $357.49M USD | +10.5% | +25.2% | 26.3% | |
| LTM Mar 2026 | $350.27M USD | +5.7% | +7.9% | 52.3% | |
| LTM Jun 2026 | $281.09M USD | -1.1% | +2.3% | 62.5% | |
| LTM Sep 2026 | $94.24M USD | +24.7% | +34.4% | — | |
| LTM Sep 2026 | $90.71M USD | +34.9% | +125.7% | 1471.2% | |
| LTM Jun 2026 | $83.07M USD | +33.3% | +188.9% | — | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $82.59M USD | +51.8% | +67.0% | — |
| LTM Jun 2026 | $71.99M USD | +448.5% | +83.8% | — | |
| LTM Mar 2026 | $58.02M USD | +16.7% | -2.9% | — | |
| Peer median (excluding APGE) | — | +24.7% | +25.2% | 62.5% | |
Competitors are the stored peer set for APGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 1.42M |
| Gross Profit | 0 | 0 | 0 | (1.42M) |
| Gross Margin | — | — | — | — |
| Research & Development | 27.79M | 68.42M | 167.87M | 214.71M |
| Selling, General & Admin | 2.94M | 24.58M | 49.01M | 70.88M |
| Operating Expenses | 30.73M | 93M | 216.87M | 284.18M |
| Depreciation & Amortization | 0 | 9.02M | 189K | 1.42M |
| EBITDA | (39.79M) | (74.97M) | (181.94M) | (254.15M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (30.73M) | (93M) | (216.87M) | (285.6M) |
| Operating Margin | — | — | — | — |
| Interest Income | 92K | 9.02M | 34.74M | 30.03M |
| Interest Expense | 9.15M | 0 | 0 | 0 |
| Other Income / Expenses | (9.06M) | 9.02M | 34.74M | 30.03M |
| Income Before Tax | (39.79M) | (83.99M) | (182.13M) | (255.57M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 18K | 278K |
| Net Income | (39.79M) | (83.99M) | (182.15M) | (255.84M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (0.79) | (1.66) | (3.30) | (4.22) |
| EPS (Diluted) | (0.79) | (1.66) | (3.30) | (4.22) |
| Weighted Avg Shares | 50.67M | 50.66M | 55.19M | 60.69M |
| Weighted Avg Shares (Diluted) | 50.67M | 50.66M | 55.19M | 60.69M |
Apogee Therapeutics, Inc.
NASDAQ:APGE
Intrinsic Alpha fair value
Locked
Current Price
$135.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.